Frontiers research topics,
Journal Year:
2023,
Volume and Issue:
unknown
Published: Jan. 1, 2023
it
is
a
pioneering
approach
to
the
world
of
academia,
radically
improving
way
scholarly
research
managed.The
grand
vision
Frontiers
where
all
people
have
an
equal
opportunity
seek,
share
and
generate
knowledge.Frontiers
provides
immediate
permanent
online
open
access
its
publications,
but
this
alone
not
enough
realize
our
goals.
journal
seriesThe
series
multi-tier
interdisciplinary
set
openaccess,
journals,
promising
paradigm
shift
from
current
review,
selection
dissemination
processes
in
academic
publishing.All
journals
are
driven
by
researchers
for
researchers;
therefore,
they
constitute
service
community.At
same
time,
operates
on
revolutionary
invention,
tiered
publishing
system,
initially
addressing
specific
communities
scholars,
gradually
climbing
up
broader
public
understanding,
thus
serving
interests
lay
society,
too.
Dedication
qualityEach
article
landmark
highest
quality,
thanks
genuinely
collaborative
interactions
between
authors
review
editors,
who
include
some
world's
best
academicians.Research
must
be
certified
peers
before
entering
stream
knowledge
that
may
eventually
reach
-and
shape
society;
only
applies
most
rigorous
unbiased
reviews.Frontiers
revolutionizes
freely
delivering
outstanding
research,
evaluated
with
no
bias
both
social
point
view.By
applying
advanced
information
technologies,
catapulting
into
new
generation.
Viruses,
Journal Year:
2024,
Volume and Issue:
16(2), P. 203 - 203
Published: Jan. 29, 2024
Vaccine
development
against
SARS-CoV-2
has
been
highly
successful
in
slowing
down
the
COVID-19
pandemic.
A
wide
spectrum
of
approaches
including
vaccines
based
on
whole
viruses,
protein
subunits
and
peptides,
viral
vectors,
nucleic
acids
developed
parallel.
For
all
types
vaccines,
good
safety
efficacy
have
obtained
both
preclinical
animal
studies
clinical
trials
humans.
Moreover,
emergency
use
authorization
granted
for
major
vaccines.
Although
high
demonstrated,
rare
cases
severe
adverse
events
detected
after
global
mass
vaccinations.
Emerging
variants
possessing
enhanced
infectivity
affected
vaccine
protection
requiring
re-design
re-engineering
novel
candidates.
Furthermore,
insight
is
given
into
preparedness
emerging
variants.
Frontiers in Immunology,
Journal Year:
2023,
Volume and Issue:
14
Published: Nov. 15, 2023
Coronavirus
disease
(Covid-19)
has
not
only
shaped
awareness
of
the
impact
infectious
diseases
on
global
health.
It
also
provided
instructive
lessons
for
better
prevention
strategies
against
new
and
current
major
importance.
Tuberculosis
(TB)
is
a
health
threat
caused
by
Vaccines,
Journal Year:
2024,
Volume and Issue:
12(2), P. 140 - 140
Published: Jan. 29, 2024
Vaccine-induced
immunity
wanes
over
time
and
warrants
booster
doses.
We
investigated
the
long-term
(32
weeks)
immunogenicity
safety
of
a
third,
homologous,
open-label
dose
TURKOVAC,
administered
12
weeks
after
completion
primary
series
in
randomized,
controlled,
double-blind,
phase
2
study.
Forty-two
participants
included
analysis
were
evaluated
for
neutralizing
antibodies
(NAbs)
(with
microneutralization
(MNT50)
focus
reduction
(FRNT50)
tests),
SARS-CoV-2
S1
RBD
(Spike
Receptor
Binding
Domain),
whole
ELISA)
IgGs
on
day
injection
at
1,
2,
4,
8,
16,
24,
32
thereafter.
Antibody
titers
increased
significantly
from
week
1
remained
higher
than
pre-booster
until
least
4
(week
8
SARS-CoV-2)
(p
<
0.05
all).
Seroconversion
(titers
≥
4-fold
compared
with
pre-immune
status)
persisted
16
(MNT50:
6-fold;
FRNT50:
5.4-fold)
NAbs
(7.9-fold)
(9.4-fold)
IgGs.
Nine
(20.9%)
tested
positive
RT-PCR
between
vaccination;
none
them
hospitalized
or
died.
These
findings
suggest
that
boosting
TURKOVAC
can
provide
effective
protection
against
COVID-19
reduce
severity
disease.
Immunology,
Journal Year:
2024,
Volume and Issue:
172(2), P. 313 - 327
Published: March 10, 2024
Abstract
This
study
longitudinally
evaluated
the
immune
response
in
individuals
over
a
year
after
receiving
three
doses
of
an
inactivated
SARS‐CoV‐2
vaccine,
focusing
on
reactions
to
Omicron
breakthrough
infections.
From
63
blood
samples
37
subjects,
results
showed
that
third
booster
enhanced
antibody
against
Alpha,
Beta,
and
Delta
VOCs
but
was
less
effective
Omicron.
Although
titres
decreased
post‐vaccination,
SARS‐CoV‐2‐specific
T‐cell
responses,
both
CD4
+
CD8
,
remained
stable.
infections
significantly
improved
neutralization
various
VOCs,
including
However,
boost
antibodies
WT,
variants
more
pronounced.
Regarding
T
cells,
infection
predominantly
boosted
response,
intensity
spike
protein‐specific
roughly
comparable
between
WT
BA.5.
Journal of Immunology Research & Reports,
Journal Year:
2024,
Volume and Issue:
4(1), P. 1 - 5
Published: Feb. 19, 2024
Background/Introduction:
The
SARS-CoV-2
B.1.1.529
variant
(Omicron)
has
shown
high
infectivity
worldwide,
even
in
vaccinated
patients.
Little
is
known
about
how
well
naturally
acquired
immunity
protect
against
further
COVID-19
infections
unvaccinated
or
We
investigated
whether
vaccination
still
warranted,
and
if
so,
what
type
of
vaccine
should
be
used.
Future Virology,
Journal Year:
2024,
Volume and Issue:
19(2-4), P. 127 - 143
Published: March 3, 2024
The
global
pandemic
due
to
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2),
has
led
∼6.9
million
deaths
and
affected
∼767
people
globally.
approved
vaccines
have
contributed
significantly
in
reducing
disease
severity
mortality.
However,
new
infections
post
vaccination
the
lack
of
specific
antivirals
encouraged
research
using
multiple
approaches
design
novel
therapeutics
against
COVID-19.
Recent
studies
on
applications
RNAi
provide
substantial
evidence
prospects
this
technique
SARS-CoV-2.
Progress
field
computational
analysis
delivery
methods
also
promises
safe
effective
implementation
This
review
deals
with
possible
challenges
